# Eledoisin: The NK3-Preferring Tachykinin from Octopus Salivary Glands
> Research Use Only (RUO). Eledoisin and related tachykinin peptides are described here strictly as laboratory research reagents for in-vitro and biochemical study. Nothing below is a human, veterinary, clinical, diagnostic, or therapeutic claim, and no dosing guidance is implied. Handle as a research chemical under appropriate institutional safety practices.
Eledoisin is an 11-residue tachykinin with a distinctive pedigree: unlike the amphibian-skin tachykinins, it was isolated from the posterior salivary glands of the Mediterranean octopus Eledone. It was among the first non-mammalian tachykinins ever characterized, and within the modern tachykinin family it is the prototypical NK3-preferring agonist. Together with the NK1-preferring physalaemin and the NK2-preferring kassinin, eledoisin completes the classic trio of natural agonists that defined the three neurokinin receptor subtypes.
A cephalopod tachykinin and the origins of the field
Eledoisin holds a foundational place in peptide pharmacology. Its discovery in octopus salivary glands demonstrated that the tachykinin blueprint extends far beyond vertebrates, and its remarkable potency made it an early workhorse for studying smooth-muscle and cardiovascular responses. Classic pharmacology described eledoisin's actions on extravascular smooth muscle Br J Pharmacol Chemother, 1962 and its powerful effect on systemic arterial blood pressure, where it ranked among the most potent natural vasodepressor peptides known at the time Br J Pharmacol Chemother, 1963. Synthetic chemistry quickly followed, with structure–activity studies on peptides related to eledoisin establishing how the molecule's sequence governs its activity Experientia, 1964.
Erspamer and colleagues, who systematically surveyed the bioactive amines and peptides of amphibian skin and other "non-mammalian" tissues, recognised eledoisin as a member of a then-novel class of potent hypotensive, sialogogue, and smooth-muscle-stimulating peptides. That comparative-pharmacology programme — the same effort that yielded physalaemin from frog skin — established the tachykinins as a coherent peptide family spanning molluscs, amphibians, and mammals. Eledoisin's cephalopod origin was a key piece of evidence that the tachykinin blueprint long predates the vertebrates.
Structure: the conserved tachykinin core
Like all tachykinins, eledoisin terminates in the obligatory C-terminal motif Phe-Xaa-Gly-Leu-Met-NH₂, the pharmacophore responsible for receptor engagement and rapid smooth-muscle contraction. Its N-terminal residues — distinct from those of the amphibian and mammalian members — bias the molecule toward the NK3 receptor. This is the same structure–activity logic seen across the family: a conserved C-terminus shared by every tachykinin, paired with a variable N-terminus that tunes receptor preference. Eledoisin is the cleanest natural example of an N-terminal sequence that swings selectivity all the way to NK3.
| Property | Substance P | Physalaemin | Kassinin | Eledoisin |
|---|---|---|---|---|
| Length | 11 residues | 11 residues | 12 residues | 11 residues |
| Origin | Mammalian | Physalaemus frog | Kassina frog | Eledone octopus |
| Conserved motif | FXGLM-NH₂ | FXGLM-NH₂ | FXGLM-NH₂ | FXGLM-NH₂ |
| Receptor preference | NK1 | NK1 | NK2 | NK3 |
| Classic role | Native NK1 ligand | NK1 reference | NK2 reference | NK3 reference |
Receptor pharmacology: anchoring the NK3 category
Before the neurokinin receptors were cloned, pharmacologists named tachykinin responses by their most potent natural agonist — and the "eledoisin-preferring" profile became the operational definition of what is now the NK3 receptor. Studies characterizing neurokinin receptors with selective agonists in tissues such as the guinea-pig urinary bladder used eledoisin and related peptides to discriminate receptor subtypes Eur J Pharmacol, 1992. The advent of selective NK3 radioligands, such as the scyliorhinin II derivative, refined this picture and provided quantitative tools to map NK3 binding sites that eledoisin had originally helped define Peptides, 1990.
Molecular dissection of the receptors themselves reinforced eledoisin's role. Chimeric NK1/NK3 receptor constructs were used to identify the domains determining agonist selectivity, work that depended on contrasting NK1- and NK3-preferring ligands J Biol Chem, 1993. Comparative neuroanatomy added another layer, documenting species differences in tachykinin receptor distribution that are essential context when extrapolating eledoisin pharmacology between model organisms J Comp Neurol, 2005.
Conformation and the membrane-association model
Like other tachykinins, eledoisin is a flexible, amphiphilic peptide whose biologically active conformation is thought to form at the membrane interface. The prevailing model holds that the peptide first partitions onto the lipid bilayer, adopting an ordered C-terminal geometry, and then presents its conserved Phe-Xaa-Gly-Leu-Met-NH₂ pharmacophore to the receptor's transmembrane binding pocket. This "membrane-catalysis" view — developed across the tachykinin family and well documented for physalaemin — frames why subtle N-terminal substitutions shift receptor preference: they tune how the peptide docks and orients at the bilayer before engaging the receptor. For researchers, eledoisin is the NK3-skewed reference point in that structure–conformation–selectivity continuum.
Documented bioactivity in research models
Eledoisin displays the broad, potent tachykinin spectrum:
- •Vasodepressor activity. Its profound lowering of arterial blood pressure was one of its earliest and most striking documented effects Br J Pharmacol Chemother, 1963.
- •Smooth-muscle contraction. Eledoisin contracts extravascular Br J Pharmacol Chemother, 1962 and gastrointestinal smooth muscle, including intestinal preparations from ruminants Folia Vet Lat, 1977.
- •Vascular permeability. As an NK-active tachykinin, eledoisin contributes to the control of vascular permeability and vascular smooth muscle in tissues such as the respiratory tract Acta Otolaryngol Suppl, 1989.
- •Epithelial ion transport. Eledoisin (with kassinin) stimulates ion transport across frog skin, a tractable native epithelium for tachykinin studies Peptides, 2004.
These are research findings in defined assay systems, reported only to characterize the reagent's documented experimental behavior.
Why eledoisin is a useful research reagent
For tachykinin and neurokinin-receptor researchers, eledoisin offers advantages distinct from the NK1- and NK2-preferring peptides:
1. NK3 reference agonist. It anchors the eledoisin-preferring (NK3) response category in both classical and modern pharmacology Eur J Pharmacol, 1992.
2. Receptor-discrimination tool. Paired with NK1- and NK2-preferring agonists, it completes a three-agonist panel for resolving receptor subtype identity in mixed-expression tissues.
3. High potency. Its strong vasodepressor and smooth-muscle activity make it a sensitive functional probe Br J Pharmacol Chemother, 1963.
4. Deep structural literature. Decades of synthetic analogue work give a rich structure–activity reference Experientia, 1964.
It pairs naturally with the NK1-preferring physalaemin, the NK2-preferring kassinin, the bradykinin homologue maximakinin, and vasoactive peptides such as bradykinin in comparative research panels.
Handling and reconstitution notes
Synthetic eledoisin supplied for research is typically lyophilized and, as a C-terminally amidated undecapeptide, is generally water-soluble. Standard practice applies: review the certificate of analysis for identity and purity, confirm purity by HPLC and mass spectrometry, and select a vehicle following a solubility guide. Document reconstitution carefully per standard reconstitution practice, and apply ordinary supplier-evaluation diligence when sourcing material.
Summary
Eledoisin is an 11-residue tachykinin from octopus (Eledone) salivary glands, carrying the conserved Phe-Xaa-Gly-Leu-Met-NH₂ motif and acting as the prototypical NK3-preferring agonist. Historically central to the discovery of non-mammalian tachykinins and to the classification of neurokinin receptors, and documented as a potent vasodepressor and smooth-muscle agonist, it remains a foundational reagent for tachykinin and NK3 receptor research — the NK3 partner that completes the natural agonist trio alongside the NK1-preferring substance P/physalaemin and the NK2-preferring kassinin.
---
This article is provided for informational and research purposes only. Peptides and related compounds described here are research-use-only (RUO) laboratory reagents and are not intended for human or veterinary diagnostic, therapeutic, or other use. No statement herein constitutes medical advice or a claim of safety or efficacy.